Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3768625 | 0.85 | HTR6 (0.46) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL155232 | 0.83 | TTR (0.50) | ALDH1A1KDM4EGAACA1CA2 | |
| Anthracene SCHEMBL27538789 | 0.83 | TTR (0.50) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL29623319 | 0.83 | TTR (0.50) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL1394931 | 0.82 | TTR (0.48) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL19025117 | 0.82 | TTR (0.48) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL1394934 | 0.82 | TTR (0.48) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL528644 | 0.82 | CA2 (0.68) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL725590 | 0.82 | ALDH1A1 (0.43) | ALDH1A1KDM4EGAACA1CA2 | |
| SCHEMBL11680739 | 0.82 | TTR (0.48) | ALDH1A1KDM4EGAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9926274-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9676703-B2 | Production method for 3,3-dimethyl-3,4-dihydro-1H-quinoxalin-2-one derivative and intermediate for said production method | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-2650282-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| EP-2650283-B1 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO (JP) | 2017-06-07 | — | — | EP | disclosed |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2016-07-14 | — | — | US | disclosed |
| EP-3031802-A1 | PRODUCTION METHOD FOR 3, 3-DIMETHYL-3, 4-DIHYDRO-1H-QUINOXALINE-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | Santen Pharmaceutical Co., Ltd (JP) | 2016-06-15 | — | — | EP | disclosed |
| US-9255070-B2 | Method of deuteration using mixed catalyst | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 2016-02-09 | — | — | US | disclosed |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | NIPPON SODA CO (JP) | 2015-05-21 | — | — | US | disclosed |
| US-9000156-B2 | Process for producing substituted methylamine compound and triazine derivative | NIPPON SODA CO., LTD. (JP) | 2015-04-07 | — | — | US | disclosed |
| WO-2004037776-A2 | NOVEL COMPOUNDS AND THEIR USE AS PRAR-MODULATORS | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| WO-2004037775-A1 | NOVEL COMPOUNDS USEFUL IN TREATING PPAR MEDIATED DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | disclosed |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | SHIONOGI & CO., LTD. | 2003-02-06 | — | — | US | disclosed |
| US-6506789-B2 | For prophylaxis and therapy of itching derived from contact dermatitis, allergic conjunctivitis, urticaria, atopic dermatitis | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | ARIMURA AKINORI (JP) | 2002-05-16 | — | — | US | disclosed |
| CN-1304320-A | Drug composition containing PGD antagonists for curing inthing | SHIONOGI & CO (JP) | 2001-07-18 | — | — | CN | disclosed |
| EP-1084711-A1 | REMEDIES FOR ITCHING CONTAINING PGD 2? ANTAGONISTS | SHIONOGI & CO., LTD. (JP) | 2001-03-21 | — | — | EP | disclosed |
| US-5691319-A | ANTICARCINOGENIC AGENTS | SANKYO COMPANY, LIMITED (JP) | 1997-11-25 | — | — | US | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170247342-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | CBR3, NOS3, CBR1 | ALDH1A1 965/4885KDM4E 1362/4885GAA 2799/4885 |
| US-20160200690-A1 | PRODUCTION METHOD FOR 3,3-DIMETHYL-3,4-DIHYDRO-1H-QUINOXALIN-2-ONE DERIVATIVE AND INTERMEDIATE FOR SAID PRODUCTION METHOD | CBR3, NOS3, CBR1 | ALDH1A1 1041/4885KDM4E 1301/4885GAA 2900/4885 |
| US-20150141653-A1 | PROCESS FOR PRODUCING SUBSTITUTED METHYLAMINE COMPOUND AND TRIAZINE DERIVATIVE | INMT, BHMT2, HNMT | ALDH1A1 3841/4885KDM4E 797/4885GAA 1736/4885 |
| US-20020058693-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | ALDH1A1 969/4885KDM4E 4756/4885GAA 2996/4885 |
| US-20030027854-A1 | Methods for the treatment of itching comprising administering PGD2 receptor antagonists | HRH2, PTGER2, PTGDR2 | ALDH1A1 969/4885KDM4E 4756/4885GAA 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.